겸상 적혈구증 치료 시장 규모, 점유율, 성장 분석 : 치료법별, 최종 용도별, 지역별 - 업계 예측(2026-2033년)

Sickle Cell Disease Treatment Market size was valued at USD 3.1 Billion in 2024 and is poised to grow from USD 3.76 Billion in 2025 to USD 17.73 Billion by 2033, growing at a CAGR of 21.4% during the forecast period (2026-2033).

The escalating prevalence of sickle cell disease, particularly in regions like Africa, the Middle East, and India, is expected to significantly drive demand for treatment options. Contributing factors include insufficient early detection, low awareness levels, and genetic factors. Additionally, heightened investments in research and development of innovative therapies may open new avenues for companies focused on sickle cell treatment. Government and non-profit initiatives aimed at raising awareness will further enhance market potential. Furthermore, the introduction of new drugs and the expansion of treatment pipelines are anticipated to bolster long-term market growth. However, challenges such as safety concerns surrounding new treatments, a complicated regulatory environment for genetic therapies, and ongoing awareness deficits may hinder the sector's advancement.

Top-down and bottom-up approaches were used to estimate and validate the size of the Sickle Cell Disease Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Sickle Cell Disease Treatment Market Segments Analysis

Global Sickle Cell Disease Treatment Market is segmented by Treatment, End-use and region. Based on Treatment, the market is segmented into Blood Transfusion, Bone Marrow Transplant, Pharmacotherapy (Hydroxyurea, Branded Products). Based on End-use, the market is segmented into Hospitals, Specialty Clinics, Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Sickle Cell Disease Treatment Market

The rise in sickle cell disease cases globally can be attributed to genetic factors and insufficient early diagnosis. Regions such as Africa, India, and the Middle East experience particularly high prevalence rates, identifying them as critical markets for treatment solutions. The urgent need for effective therapies in these areas presents significant opportunities for providers specializing in sickle cell disease treatments. As awareness and understanding of the condition grow, the demand for innovative treatments is expected to increase, driving growth in the market and prompting advancements in medical interventions tailored to meet the needs of affected populations.

Restraints in the Sickle Cell Disease Treatment Market

The Sickle Cell Disease Treatment market faces significant challenges due to a general lack of awareness about the symptoms associated with the condition. This limited understanding often leads to delayed diagnoses, resulting in numerous cases remaining unidentified or being recognized too late for effective treatment. Additionally, insufficient diagnostic facilities contribute to the problem, further hindering timely interventions. As a consequence, the demand for treatment options in the Sickle Cell Disease sector is adversely affected. Enhancing awareness and improving diagnostic capabilities are crucial for fostering better health outcomes and promoting market growth moving forward.

Market Trends of the Sickle Cell Disease Treatment Market

The Sickle Cell Disease Treatment market is witnessing a growing trend of collaborations aimed at enhancing accessibility to therapies and treatments globally. Acknowledging the disparities in treatment availability across regions, stakeholders including governments, non-profit organizations, and healthcare companies are increasingly partnering to improve affordability and distribution of novel therapies. This collaborative approach not only aims to bridge the treatment gap but also fosters innovation and market expansion. As accessibility improves, patient adoption rates for new treatments are expected to rise, ultimately driving revenue growth and creating a more equitable healthcare landscape for those affected by sickle cell disease.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Driver & Opportunities
  • Restraints & Challenges
• Porters Analysis & Impact
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement
• Regulatory Landscape
• Case Studies

Global Sickle Cell Disease Treatment Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Bone Marrow Transplant
• Blood Transfusion
• Pharmacotherapy
  • Hydroxyurea
  • Branded Products

Global Sickle Cell Disease Treatment Market Size by End-use & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Others

Global Sickle Cell Disease Treatment Market Size & CAGR (2026-2033)

• North America, (Treatment, End-use)
  • US
  • Canada
• Europe, (Treatment, End-use)
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
• Asia-Pacific, (Treatment, End-use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America, (Treatment, End-use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa, (Treatment, End-use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emmaus Medical, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Addmedica
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medunik USA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Global Blood Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bluebird Bio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aruvant Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Glycomimetics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Editas Medicine, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CRISPR Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hemanext
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendation